January 6, 2023 07:12 AM ESTUpdated 11:09 AM

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ While an FDA ruling on Eisai and Biogen’s Alzheimer’s drug lecanemab is imminent, new Biogen CEO Chris Viehbacher is splitting the role of R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bio­gen names de­vel­op­ment chief as it braces for lecanemab de­ci­sion; Zymeworks CMO is shown the door

Copy Chief

Editor

Sign up to read this article for free.

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door